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Angiotensin converting enzyme (ACE) inhibitors
and beta-blockers have together become the back-
bone of the treatment of chronic heart failure (CHF)
as both classes of drugs have been shown to reduce
morbidity and mortality [1]. In addition, patients
with CHF generally receive a number of other drugs,
which include diuretics, digoxin, vasodilators (like
nitrates, and calcium channel blockers), anti-ar-
rhythmic drugs, anticoagulants, and more recently
statins. Although these latter classes of drugs may be
indicated for special indications (such as atrial fibril-
lation) none of them has been overall shown to im-
prove outcome. This is in contrast with two other
classes of drugs which were found to further reduce
morbidity and mortality in patients with CHF when
added to maximal medication, i.e. angiotensin II re-
ceptor blockers (ARBs) and aldosterone receptor an-
tagonists (ARAs) [2–5].
In recent years, ARAs have also been increasingly
studied in patients with established CHF and in
those with LV dysfunction/CHF after MI, although
maybe not quite as much as ARBs. Aldosterone lev-
els are increased in patients with CHF [6], and it is
generally assumed that ACE inhibitors lead to a re-
duction in plasma aldosterone levels [7], probably by
lowering the production of aldosterone from the
adrenal gland by preventing angiotensin II and stim-
ulation of the AT1 receptor. However, it has been ob-
served that in a significant proportion of patients
treated with ACE inhibitors the aldosterone levels in-
crease again after several months [8]. Therefore, a
role for ARAs in the treatment of CHF on top of
ACE inhibition or ARBs seems reasonable. It has
been discovered that next to the modulation of gene
expression and translation of proteins that regulate
electrolyte and fluid balance and subsequent blood-
pressure homeostasis by aldosterone, it has rapid so-
called non-genomic effects [9, 10]. These non-geno-
mic effects include activation of pathways involved
in inflammation, oxidative signalling, and collagen
formation. Treatment with ARAs leads to suppres-
sion of these pathways and results in a reduction of
collagen formation and myocardial fibrosis, and im-
provement of endothelial function [11]. Under cer-
tain circumstances, aldosterone also may have sev-
eral effects that could contribute to sudden cardiac
death. This includes stimulation of central sympa-
thetic drive, release of norepinephrine from periph-
eral sympathetic nerves, a decrease in heart rate
variability and baroreceptor function, and a recently
observed blockade of a mechanism that increases so-
dium channel density or increases calcium channel
density and then decreases the transient outward
current that would ameliorate QT prolongation, a
risk factor for sudden death [12].
The two ARAs which have been studied in clini-
cal trials are spironolactone and eplerenone. Spiro-
nolactone is a nonselective antagonist of the aldos-
terone receptor, binding also to other steroid recep-
tors and causing a significant percentage of patientsto have adverse effects such as gynaecomastia. Epler-
enone is the first of a new class of drugs known as
selective aldosterone receptor antagonists, which has
a minimal effect at other steroid receptors.
Spironolactone was initially developed for the
treatment for hypertension. Later its role in the
treatment of CHF patients was studied. In the Ran-
domized Aldactone Evaluation Study (RALES) trial,
in 1663 patients with severe CHF (NYHA class III or
IV) and a left ventricular ejection fraction of ≤35%,
administration of spironolactone (25 mg) as add-on
therapy to ACE inhibitors plus standard treatment
(loop diuretics, digoxin and not frequently beta-
blockers) had no significant effect on blood pressure
or heart rate (‘genomic effect’) [4]. Despite this it re-
sulted in 26% mortality reduction in cardiovascular
mortality after a 24 month follow-up period (num-
bers needed to treat 11) (Fig. 1). However, spirono-
lactone was associated with a higher incidence of
gynaecomastia or breast pain (10 vs 1%), whereas
the incidence of severe hyperkalemia was similar (2
vs 1%). The role of spironolactone in patients with
less advanced CHF has not been subject of random-
ized or large clinical trials. Furthermore, only 10%
of the patients were taking beta-blockers and most
patients received <50% of their recommended doses
of ACE inhibitors.
Eplerenone was developed more recently. Based on
its selectivity it has a more favourable side effect pro-
file. In the Eplerenone Post-Acute Myocardial Infarc-
tion Heart Failure Efficacy and Survival Study (EPHE-
SUS), in 6632 patients with left ventricular ejection
fraction of ≤40% and chronic heart failure following
an acute myocardial infarction, treatment with the
more selective eplerenone (25 mg), resulted in a 17%
reduction in cardiovascular mortality over a 16 month
follow-up period (numbers needed to treat 44) (Fig. 1)
[5]. This risk reduction was observed on top of treat-
ment with ACE inhibitors or ARBs (87%), diuretics
(61%) and beta-blockers (75%). Treatment with epler-
enone was associated with a higher incidence of hy-
perkalemia (5.5 vs 3.9%) but lower incidence of hypo-
kalemia (8.4 vs 13.1%) while gynaecomastia was not
increased (0.5 vs 0.6%).
ARAs may not only have structural effects on left
ventricular function, but they may also reduce sudden
death. This was first suggested in RALES [4]. In the
EPHESUS it was shown that eplerenone caused a re-
duction of 37% in the incidence of sudden cardiac
death within 30-days after acute myocardial infarction
[13]. During the episode, i.e. the first month after
acute myocardial infarction, the risk of sudden death
is particularly high (Fig. 2) [14]. Early implantation
of Implantable Cardioverter-Defibrillators was not
found to be effective when performed within the first
month after myocardial infarction [15], although later
implantation of such devices have clearly shown their
benefit. The beneficial effect of eplerenone in EPHE-
SUS was observed despite the fact that treatment
was initiated at a mean of 7.3 days after myocardial in-
farction, and an even earlier start, i.e. on day one,
could potentially lead to even greater reduction in
sudden cardiac death. Administration of ARAs was
shown to be feasible within 24 h after myocardial in-
farction in a study on the effect of spironolactone on
left ventricular remodelling [16]. Therefore, one may
speculate that earlier use of eplerenone (in EPHESUS)
could have led to an even larger beneficial effect.
In conclusion, when added to conventional thera-
py ARAs show benefits which are in addition to
those conferred by ACE inhibitors and/or ARBs and
beta-blockers. In eplerenone treated patients a sub-
stantial reduction of sudden cardiac death is ob-
served early after myocardial infarction. The above
mentioned non-genomic effects may possibly play a
role in the observed effects.
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Fig. 1 All-cause mortality in RALES and EPHESUS (adapted from [4] and [5]).
Mean follow-up period is 24 months in RALES and 16 months in EPHESUS
Fig. 2 The risk of sudden cardiac death after myocardial infarction (adapted
from [12])195 I.C.C. van der Horst et al.
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